ferrous sulfate 125 MG/ML Oral Solution

Drug interactions

The label outlines various drug interactions with combined oral contraceptives (COCs) that may affect their efficacy and plasma concentrations.

• majorCYP3A4 inducers — may decrease the effectiveness of COCs or increase breakthrough bleeding
• majorphenytoin — may decrease the effectiveness of COCs
• majorbarbiturates — may decrease the effectiveness of COCs
• majorcarbamazepine — may decrease the effectiveness of COCs
• majorbosentan — may decrease the effectiveness of COCs
• majorfelbamate — may decrease the effectiveness of COCs
• majorgriseofulvin — may decrease the effectiveness of COCs
• majoroxcarbazepine — may decrease the effectiveness of COCs
• majorrifampicin — may decrease the effectiveness of COCs
• majortopiramate — may decrease the effectiveness of COCs
• majorrifabutin — may decrease the effectiveness of COCs
• majorrufinamide — may decrease the effectiveness of COCs
• majoraprepitant — may decrease the effectiveness of COCs
• majorSt. John’s wort — may decrease the effectiveness of COCs
• majorcolesevelam — significantly decreases the AUC of EE
• moderateatorvastatin — increases AUC values for EE
• moderaterosuvastatin — increases AUC values for EE
• moderateascorbic acid — may increase plasma EE concentrations
• moderateacetaminophen — may increase plasma EE concentrations
• moderateCYP3A4 inhibitors — may increase plasma hormone concentrations
• moderateHIV protease inhibitors — significant changes in plasma concentrations of estrogen and/or progestin
• moderateHCV protease inhibitors — significant changes in plasma concentrations of estrogen and/or progestin
• majorlamotrigine — may reduce seizure control
• moderatethyroid hormone — may need increased doses of thyroid hormone
• majorombitasvir/paritaprevir/ritonavir — potential for ALT elevations